Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Humana (HUM) and 10x Genomics (TXG)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zoetis (ZTS – Research Report), Humana (HUM – Research Report) and 10x Genomics (TXG – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zoetis (ZTS)
J.P. Morgan analyst Chris Schott maintained a Buy rating on Zoetis today and set a price target of $190.00. The company’s shares closed last Friday at $129.91.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
Zoetis has an analyst consensus of Moderate Buy, with a price target consensus of $147.70, which is an 11.5% upside from current levels. In a report released today, TipRanks – xAI also upgraded the stock to Buy with a $145.00 price target.
See today’s best-performing stocks on TipRanks >>
Humana (HUM)
In a report released today, Lisa Gill from J.P. Morgan maintained a Hold rating on Humana, with a price target of $180.00. The company’s shares closed last Friday at $181.30.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
Currently, the analyst consensus on Humana is a Hold with an average price target of $226.88, implying a 26.9% upside from current levels. In a report released yesterday, RBC Capital also downgraded the stock to Hold with a $189.00 price target.
10x Genomics (TXG)
In a report released today, Casey Woodring from J.P. Morgan maintained a Hold rating on 10x Genomics, with a price target of $17.00. The company’s shares closed last Friday at $19.66.
According to TipRanks.com, Woodring is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 10x Genomics with a $19.50 average price target, representing a 2.6% upside. In a report issued on February 5, Piper Sandler also maintained a Hold rating on the stock with a $19.00 price target.
